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PRIOR to orthotopic liver transplant (OLT), renal func-
tion in patients with end-stage liver disease (ESLD) 
may be diminished as a result ofthe hepatorenal syndrome 
(HRS); or, after OLT, the potential nephrotoxic effects of 
antirejection regimens superimposed. 
We have attempted to make a more precise definition of 
the renal effects of FK 506 and cyclosporine (Cy A) by the 
measurement of effective renal plasma flow (ERPF), the 
glomerular filtration rate (GFR), and the filtration fraction 
(FF) or GFRlERPF. EPRF, in milliliters per minute, 
measures the total plasma flow acted upon by the nephron 
mass, and is traced by orthoiodo-hippurate (131 I-OIH). It 
is both filtered by the glomerulus and cleared by the 
proximal convoluted tubules. GFR, also in milliliters per 
minute, traced by 125-1 iothalamate, is only filtered by the 
glomeruli. The FF measures the global fraction of the total 
plasma flow through the nephrons that is filtered by the 
glomeruli. Thus. FF is a measure of the integrity of the 
filtering membrane. 
It is generally believed that this membrane is a target for 
agents that are prescribed to inhibit transplanted organ 
rejection. We have, therefore, elected to elucidate and to 
compare these effects in a large popUlation of liver trans-
plantees. 
MATERIALS AND METHODS 
Group I consisted of 27 adult patients awaiting liver transplanta-
tion. Group 2 consisted of 25 recently transplanted patients 
(within 2 months), who had received specific antirejection treat-
ment only with CyA. Group 3 consisted of 116 patients, who had 
received only FK 506. 
ERPF data were related to predictive algorithms based on age 
and sex, from a group of 345 adult normal subjects prior to kidney 
transplantation, 1 32 of whom also had simultaneous GFR deter-
minations. Both ERPF2 and GFR3 were studied by previously 
described techniques based on single-injection, single-plasma 
sample procedures that have been evaluated in a wide variety of 
patients. 1,4 
RESULTS 
The mean values of ERPF, GFR, and FF, the expected 
values of each, and the percentage of deviation from the 
values of ERPF and FF are all tabulated (Table 1). One 
standard deviation is indicated by parentheses. Actual 
values for the groups are depicted as ERPF, GFR, and FF 
while expected values are indicated by the prefix exp; the 
prefix d indicates the difference form the expected normal 
value. 
Data from group 1 patients showed that ESLD alone 
was the chief contributor to the impairment of renal 
function. ERPF was diminished by 35% below expected 
normal values. In patients subsequently transplanted and 
treated with Cy A, the cumulative mean ERPF diminution 
was 53%, thus these patients begin their posttransplant 
course with a functional renal mass of less than one-half 
their expected normal value. For group 3, the mean ERPF 
was found to be 336 mUmin, or 42% below the expected 
normal value, 11% higher than that of group 2. 
These ERPF data are depicted graphically in Fig 1, 
where insignificant differences are observed between 
groups 1 and 3, but group 2 ERPF values are significantly 
lower than those of groups 1 and 3. The same general 
pattern was observed in the GFR groups (Fig 2). 
The differences between GFR among groups are signif-
icantly less than those of ERPF. All FFs and their SDs 
were significantly above expected values from matched 
normal subjects, but on the FF/ERPF regression line 
previously reported. 1 ,4 The high sigmas in both directions 
were indicative of filtering membrane damage. Values 
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Table 1. Renal Function Effects of FK 506 and CyA In Liver Transplant Recipients 
ERPF expERPF aERPF GFR expGFR a3FR 
Group n (mLimin) (mLimin) (%) (mLimin) (mLimin) (%) FF expFF 
27 360 513 -35 74 92 -15 0.21 0.18 
(147) (62) (23) (29) (28) (35) (0.11 ) (0.04) 
2 25 268 567 -53 55 78 -25 0.21 0.14 
(113) (55) (20) (22) (28) (21) (0.08) (0.05) 
3 116 336 581 -42 76 86 -9 0.23 0.15 
(152) (74) (24) (29) (28) (33) (0.10) (0.05) 
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Fig 1. The graph depicts the mean expected normal global 
milliliters per minute for all patients studied. The mean and 1 SD 
are indicated in group 1; the mean value was 35% lower for ESLD 
with a relatively wide range of error. Group 2 values (patients on 
eyA) were significantly lower, global ERPF being 53% below 
expected normal values. Group 3 values (patients on FK 506) 
were only moderately lower than those in group 1 . 
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Fig 2. The graph depicts the expected normal global GFR in 
milliliters per minute for the whole group in a manner similar to that 
shown in Fig 1; groups 1 to 3 are the same. Group 1 data from the 
pretransplant patients exhibited a mean value significantly below 
those observed in the expected normal group, but significantly less 
than that observed in ERPF. Groups 1 and 3 are not significantly 
different from each other, indicating that FK 506 had no demon-
strable effect on GFR. Group 2 values are significantly lower than 
those of group 1 though less than those of ERPF. 
above the line were compatible with leaky membranes, 
and those below the expected mean value with plugged 
membranes. • ':&.cfi ".. ~KvgSK :-. ~K_;Kg .. Af 
SUMMARY AND CONCLUSION ~K~ 
As renal mass was compromised, ie, fall in the 
ERPF, the GFR increased relatively, ie, the renal 
filtering membrane became more permeable and the 
1. The mean "cost" in milliliters per minute -o~bpia 
alone, prior to transplantation, was 35% + 23% (I 
SD). In GFR it was 15%. 
2. The additional burden of Cy A + OL T increases the 
loss in ERPF an additional 18%; in GFR, it increases 
loss another 10%. Thus, the total loss in CyA-treated 
patients was 53% and 25%, respectively. 
3. The decrease imposed by FK 506 + OLT on ERPF 
was only 7%, with no decrease in GFR. 
4. Therefore, from the renal point of view, FK 506 
would appear to be the superior drug. 
5. The large error around mean values underlines the 
desirability of performing these tests on the individ-
ual patient rather than on information from groups, 
since many values fall near the threshold of the 
azotemic range (ERPF approximately 175 mLlmin). 
a." a 
FFs gradually increased. 
7. The loss of renal function was significantly less in 
OLT patients on FK 506 than CyA. However, the 
greatest loss in expected renal function was due to 
the basic ESLD itself. 
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